Home
Preclin Consulting GmbH is a toxicology, pathology and safety assessment consulting company based in the Basel region, Switzerland. Basel is one of the leading centers for biomedical research in the world and host of large pharmaceutical industries (Novartis, Roche, Actelion) as well as of many start-ups biotech companies.
Dr Virgilio Pace is the owner and non-clinical expert of the company. His combined education and experience in general toxicology, non-clinical pharmacology and toxicological pathology makes him the ideal partner of start-ups, small and medium size companies for the identification of “Lead Candidates” and the non-clinical drug development of new chemical or biological entities.
His particular area of interest is ophthalmology. In this area, he gained a large experience with both chemical and biological entities. In this regard, Dr Pace had the responsibility for the preclinical development of the recombinant human Nerve Growth Factor (rhNGF) for the clinical indication of Neurotrophic Keratitis. This drug has been approved by EMA and is marketed in EU under the trade name of Oxervate®. Currently it is under priority review by the FDA and also obtained the “breakthrough therapy” designation.